![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1273461
¼¼°èÀÇ ºÎºñµ¿¿° Ä¡·á ½ÃÀå : ¼ºÀå, µ¿Çâ, COVID-19ÀÇ ¿µÇâ, ¿¹Ãø(2023-2028³â)Sinusitis Treatment Market - Growth, Trends, and Forecasts (2023 - 2028) |
ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È 6.4%ÀÇ CAGR·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¼¼°è Àα¸¿¡¼ COVID-19 °¨¿°ÀÇ ÆÒµ¥¹ÍÀº °¨¿°ÀÚÀÇ ºÎºñµ¿¿° °¨¿°°ú °ü·ÃÀÌ ÀÖÀ» °ÍÀ¸·Î ¿¹»óµÇ¾î ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÇ¾ú½À´Ï´Ù. 2021³â 5¿ù¿¡ National Library of Medicine¿¡ °ÔÀçµÈ ³í¹®¿¡¼´Â ÃÖ±Ù COVID-19 °¨¿°¿¡ µû¸¥ ±Þ¼º ħ½À¼º Áø±Õ¼º ºÎºñµ¿¿°À¸·Î Áø´ÜµÇ¾î Manusora University¿¡¼ Ä¡·á¸¦ ¹ÞÀº ȯÀÚ¸¦ ºÐ¼®ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. µÇ¾ú½À´Ï´Ù. ¸ðµç ȯÀÚ´Â PCR°ú CT °Ë»ç¿¡ ÀÇÇØ COVID-19·Î È®Á¤ Áø´ÜµÇ¾ú°í COVID ÈÄ Ä§½À¼º Áø±Õ¼º ºÎºñµ¿¿°À̾ú½À´Ï´Ù. ±× °á°ú, ÆÒµ¥¹Í½Ã¿¡´Â È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö¹Ç·Î ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÎºñµ¿¿°Àº ±Þ¼º ¶Ç´Â ¸¸¼ºÀÏ ¼ö ÀÖÀ¸¸ç, Ä¡·áÇÏÁö ¾ÊÀ¸¸é ¹ÚÅ׸®¾Æ ¹× ¹ÙÀÌ·¯½º¿Í °°Àº ´Ù¾çÇÑ ¼¼±ÕÀÌ ºñ°À» ¸·°Å³ª ¾×ü·Î °¡µæ Â÷°Ô µË´Ï´Ù. ºÎºñµ¿¿°À» Ä¡·áÇϰųª ¹ß°ßÇÏÁö ¾ÊÀ¸¸é ³ú³ó¾çÀ̳ª ³ú¼ö¸·¿°°ú °°Àº ÇÕº´ÁõÀ¸·Î ÁøÇàµÉ ¼ö ÀÖ½À´Ï´Ù. Áø´ÜÀ» À§ÇØ Ç÷¾× °Ë»ç, ¼¶¸ð ±â´É °Ë»ç, ºñ° ¼¼Æ÷ °Ë»ç ¹× ¾Ë·¹¸£±â °Ë»ç, ºÎºñµ¿ CT ½ºÄµ, ºÎºñµ¿ MRI µîÀ» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. Ç×»ýÁ¦¸¦ 1Â÷ Ä¡·áÁ¦·Î »ç¿ëÇϰí ÃæÇ÷ ¿ÏÈÁ¦¿Í ½ÉÇÑ ´Ü°è¿¡¼´Â ¼ö¼úÀ» ½ÃÇàÇÕ´Ï´Ù.
½ÃÀå ¼ºÀåÀº ºÎºñµ¿¿° À¯º´·ü Áõ°¡, Áø´Ü °Ë»ç ¹× Ç×»ýÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ºÎºñµ¿¿° ¼ö¼úÀÇ ±â¼ú ¹ßÀü µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ Áúº´ Áø´Ü ¹× Ä¡·á¸¦À§ÇÑ ÀÇ·á ±â±âÀÇ »ç¿ë Áõ°¡¿Í ºñ° ½ºÇÁ·¹ÀÌ, ºñ° ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀÌµå ¹× ÃæÇ÷ ¿ÏÈÁ¦¿Í °°Àº Ä¡·á¸¦À§ÇÑ ´Ù¾çÇÑ ¾à¹°ÀÇ »ç¿ëÀº ¿¹Ãø ±â°£ µ¿¾È ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀÇ Àü·Ê¾ø´Â ¼ºÀåÀÇ ÇÙ½É ¸Å°³ º¯¼öÀÔ´Ï´Ù. 2021³â 6¿ù¿¡ ¹ßÇ¥µÈ '¸¸¼º ºÎºñµ¿¿°'À̶ó´Â Á¦¸ñÀÇ ±â»ç¿¡ µû¸£¸é, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å´Â ¸¸¼º ºÎºñµ¿¿° ȯÀÚÀÇ Ä¡·á¿¡ ÀÚÁÖ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ´ë¿ë·® ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀÌµå °ü°³´Â ºÎºñµ¿ ¼ö¼ú ÈÄ ¸¸¼º ºÎºñµ¿¿° ȯÀÚ¿¡°Ô µµ¿òÀ̵˴ϴÙ.
ÀÌ ½ÃÀå¿¡¼ ȸ»çÀÇ ÁÖ¿ä Àü·«Àº ºÎºñµ¿¿° Ä¡·á¸¦À§ÇÑ ´õ ³ªÀº ¼Ö·ç¼ÇÀ» ã±â À§ÇØ ½ÅÁ¦Ç°À» Ãâ½ÃÇÏ´Â °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Clinic Barcelona 2021¿¡ µû¸£¸é ´ÜÀÏ Å¬·Ð Ç×ü´Â ¿ëÁ¾À» µ¿¹ÝÇÑ ºÎºñµ¿¿°¿¡ È¿°úÀûÀÎ Á¤¹Ð ÀÇÇÐÀÇ ÇÑ ÇüÅÂÀ̸ç, ¿À¸»¸®ÁÖ¸¿(IgE), ¸ÞÆú¸®ÁÖ¸¿(IL-5), ·¹½½¸®ÁÖ¸¿(IL-5) ¹× µÎÇʷ縿(IL4 ¥á) ¾à¹°·Î ´Ù¾çÇÑ ÀÓ»ó ½ÃÇèÀÌ ¼öÇàµÇ¾î ±× È¿°ú¸¦ ¾Ë°í ÀÖ½À´Ï´Ù. 2020³â 5¿ù, ½ºÅÄÆ÷µå ¹ÙÀÌ¿ÀµðÀÚÀο¡¼ ½ÃÀÛÇÏ¿© ÇöÀç Æ÷°¡Æ¼ ÀνºÆ¼Æ©Æ®ÀÇ ÀÚȸ»çÀÎ ½ºÅ¸Æ®¾÷ ³ª¼½º ¸ÞµðÄÃÀº ´õ ³ªÀº ºñ° ³» ¾à¹° Àü´ÞÀ» À§ÇÑ ¼Ö·ç¼ÇÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º ºÎºñµ¿¿°ÀÇ Ã¹ ¡Èİ¡ ³ªÅ¸³ª¸é ȯÀÚ°¡ Áý¿¡¼ ½º½º·Î Ä¡·áÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â »õ·Î¿î ÀåÄ¡¸¦ °³¹ßÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
µû¶ó¼ À§¿Í °°Àº ¿äÀÎÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁø ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÁøÅëÁ¦, Ç×È÷½ºÅ¸¹ÎÁ¦, ºÎ½ÅÇÇÁú È£¸£¸óÁ¦, Ç×»ýÁ¦, ¼ö¼úÀº Àü¼¼°è ºÎºñµ¿¿° Ä¡·á ½ÃÀå¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á¹ý Áß ÇϳªÀÔ´Ï´Ù. ÀüµÎµ¿, ³ªºñÇü °ñµ¿ ¹× ü°ñµ¿À» ºñ·ÔÇÑ ¹ÚÅ׸®¾Æ ºÎºñµ¿¿°¿¡´Â ÀÌ·¯ÇÑ À¯ÇüÀÇ ºÎºñµ¿¿°ÀÌ ´õ ½É°¢ÇÑ ¹®Á¦¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î Ç×»ýÁ¦°¡ ±ÇÀåµË´Ï´Ù. Æä´Ï½Ç¸°°è, ¼¼ÆÈ·Î½ºÆ÷¸°°è, ¸ÅÅ©·Î¶óÀ̵å°è µî Ç×»ýÁ¦°¡ ¿À·§µ¿¾È ÃßõµÇ¾î ¿Ô½À´Ï´Ù. 2022³â 8¿ù¿¡ National Library of Medicine¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, ºÎºñµ¿¿°ÀÇ Áõ»óÀÌ ±×·¯ÇÑ Ä¡·á¸¦ Á¤´çÈÇÏ´Â °æ¿ì Ç×»ýÁ¦°¡ ó¹æµÉ ¼ö ÀÖ½À´Ï´Ù. ºÎºñµ¿ °¨¿°¿¡ ´ëÇÑ ÀϹÝÀûÀÎ Ç×»ýÁ¦·Î´Â Augmentin, Zithromax, Leverquin, Septra, AmoxilÀÌ ÀÖ½À´Ï´Ù.
¶ÇÇÑ 2021³â 2¿ù¿¡ National Library of Medicine¿¡ °ÔÀçµÈ ³í¹®¿¡¼´Â ¸¸¼º ºÎºñµ¿¿°ÀÇ À¯º´·üÀÌ À¯·´¿¡¼ ¾à 10.9%, ¹Ì±¹¿¡¼ ¾à 13%, Çѱ¹¿¡¼ ¾à 6.95%, Áß±¹¿¡¼ ¾à 8% ±×¸®°í À̰ÍÀÌ Ç×»ýÁ¦ ¼ö¿ä Áõ°¡·Î À̾îÁú ¼ö ÀÖ´Ù°í ¸»ÇÕ´Ï´Ù. ¼ºÀÎÀÇ ±Þ¼º ºÎºñµ¿¿°À» ´õ Àß Ä¡·áÇϱâ À§Çؼ´Â ÇöÀç Ä¡·á¹ýÀ» °ËÅäÇØ¾ßÇÕ´Ï´Ù. »õ·Î¿î Ä¡·á¹ý°ú ¾à¹° °³¹ß¿¡´Â ¸¹Àº ½Ã°£, ³ë·Â, °úÇÐ ¿¬±¸ ¹× ÀÚº»ÀÌ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼ ºÎºñµ¿¿°À» ¾Î°í Àִ ȯÀÚÀÇ Ä¡·á¿¡ ´õ ³ªÀº ´ë¾È ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ °¢ ȸ»ç´Â R&D ³ë·ÂÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
ºÎºñµ¿¿°ÀÇ À¯º´·üÀÌ ³ôÀº ºÏ¹Ì´Â ºÎºñµ¿¿° Ä¡·á ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
2022³â 5¿ù¿¡ ¹ßÇ¥µÈ 'Sinusitis'¶ó´Â Á¦¸ñÀÇ ±â»ç¿Í °°ÀÌ, ºÎºñµ¿¿°Àº ¹Ì±¹¿¡¼ ÀÓ»ó ¹æ¹®ÀÇ °¡Àå ÈçÇÑ ¿øÀÎ Áß ÇϳªÀ̸ç 1 ³â µ¿¾È 7,300 ¸¸ ÀÏÀÇ È°µ¿ Á¦ÇÑ Àϼö·Î À̾îÁý´Ï´Ù. ¶ÇÇÑ, °Ç°¿¡ ´ëÇÑ Àνİú ÁÖ¿ä ¾÷üµéÀÇ Àû±ØÀûÀÎ Âü¿©°¡ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ¹Ì±¹ ½ÄǰÀǾ౹Àº Ŭ¸®¾î¾÷ ºÎºñµ¿ ÅëÁõ ¿ÏÈ Ä¡·áÁ¦ÀÇ »ç¿ëÀ» È®´ëÇÏ¿© ÄÚ¸·Èû Ä¡·á¿¡ ´ëÇÑ ÀûÀÀÁõÀ» Æ÷ÇÔ½ÃÄ×½À´Ï´Ù.
ÀÓ»ó ½ÃÇèÀº ½ÃÀå ¼ºÀåÀÇ ¶Ç ´Ù¸¥ ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù ij³ª´Ù ¼¼ÀÎÆ® Æú º´¿øÀº 80¸íÀÇ ÇÇÇèÀÚ¸¦ ´ë»óÀ¸·Î ¹«ÀÛÀ§ ÀÌÁß¸Í°Ë À§¾à ´ëÁ¶ ÀÓ»ó½ÃÇèÀ» ½Ç½ÃÇÏ¿© ºÎºñµ¿ ÆÄ¿ö ¼¼Ã´°ú ºÎºñµ¿ ¹Ì»ý¹° Àü´Þ(SNMT)ÀÌ ºÎºñµ¿ ÆÄ¿ö ¼¼Ã´°ú °¡Â¥ SNMT¿¡ ºñÇØ ¸¸¼º ºÎºñµ¿¿°(CRS) ȯÀÚÀÇ ÀÓ»ó °á°ú¸¦ 45ÀÏ À̳»¿¡ °³¼±ÇÏ´ÂÁö Å×½ºÆ®Çϱ⠽ÃÀÛÇß½À´Ï´Ù. ¿¬±¸ÀÚµéÀº SNMTÀÇ ¾ÈÀü¼º ÇÁ·ÎÇÊÀ» Á¶»çÇÏ¿© SNMT °ü·Ã CRS Áõ»ó °³¼±ÀÌ ÃÖ´ë 6°³¿ù±îÁö Áö¼ÓµÇ´ÂÁö È®ÀÎÇß½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¿¬±¸ÀÚµéÀº Ä¡·á ÀüÈÄ ºÎºñµ¿ ¹Ì»ý¹°°ú ¿°ÁõÀÇ º¯È¸¦ ÃßÀûÇÏ¿© SNMT°¡ CRS ȸº¹¿¡ ¾î¶»°Ô ±â¿©ÇÏ´ÂÁö Á¶»çÇß½À´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ ÀÓ»ó ½ÃÇèÀºÀÌ Áö¿ª¿¡¼ ´õ ³ªÀº Ä¡·á¸¦ Á¦°øÇÏ¿© ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ¿Í °°ÀÌ ºÎºñµ¿¿°ÀÇ À¯º´·ü Áõ°¡, °è¹ß Ä·ÆäÀÎ, ÀÓ»ó½ÃÇè µîÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀº ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù. ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Olympus Corporation, Medtronic plc, Stryker, Cipla Ltd., Dr. Reddy's Laboratories Ltd, Intersect ENT, Inc., Sanofi SA, Aurobindo Pharma µîÀÔ´Ï´Ù.
The Sinusitis Treatment Market is projected to register a CAGR of 6.4% during the forecast period.
The COVID-19 pandemic had an effect on the market. The outbreak of COVID-19 infections in the global population was expected to be associated with sinusitis infections in the infected patients, thereby driving the growth of the market. The article published in the National Library of Medicine in May 2021 mentioned that patients diagnosed with acute invasive fungal rhino-sinusitis associated with recent COVID-19 infection and treated at Manusora University were analyzed. All patients had a definite diagnosis of COVID-19 by PCR and CT studies with post-COVID invasive fungal sinusitis. As a result, during the pandemic, the Sinusitis Treatment Market is expected to grow because of the increased demand for effective treatment.
Sinusitis can be acute or chronic, with different germs such as bacteria and viruses blocking the nasal cavities or filling them with fluid if not treated. Sinusitis can progress to complications such as a brain abscess and meningitis if it is not treated or detected. Blood tests, ciliary function tests, nasal cytology & allergy testing, sinus CT scans, and sinus MRIs are all available for diagnostic purposes. Antibiotics are the first line of treatments followed by decongestants and surgery at a severe stage.
Market growth can be attributable to a variety of factors, including the rising prevalence rate of sinusitis, increased demand for diagnostic tests and antibiotics, and technological advancements in sinusitis surgery.
Additionally, the growing use of medical devices for disease diagnosis and treatment, as well as the use of various medications for treatment such as nasal sprays, nasal corticosteroids, and decongestants, are key parameters in the unprecedented growth of the sinusitis treatment market during the forecast period. According to the article titled ' Chronic Sinusitis' published in June 2021, corticosteroids are frequently utilized in the treatment of people with chronic sinusitis. Large-volume corticosteroid irrigation helps patients with chronic sinusitis after sinus surgery.
The primary strategies of the companies in this market are new product launching to find out better solution for sinusitis treatment. For instance, according to Clinic Barcelona 2021, monoclonal antibodies are effective form of precision medicine in sinusitis with polyps and different clinical trials have been carried out with the drugs omalizumab (IgE), mepolizumab (IL-5), reslizumab (IL-5) and dupilumab (IL4 ¥á) to know there effectiveness. In May 2020, Nasus Medical, a startup born out of Stanford Biodesign and now a Fogarty Institute company, is working on a solution for better intra-nasal drug delivery. When the first signs of chronic sinusitis arise, their novel device promises to allow patients to treat themselves at home.
Thus the above-mentioned factors are exected to drive the growth of the market during the forecast period.
Analgesics, Antihistamines, Corticosteroids, Antibiotics, and Surgery are among the treatments available in the global sinusitis treatment market. Antibiotics are recommended for bacterial sinusitis involving the frontal, sphenoid, or ethmoid sinuses, as this type of sinusitis can produce more serious problems. Antibiotics like Penicillins, cephalosporins, and macrolides have been recommended for a long time. According to the article published in the National Library of Medicine in August 2022 Antibiotics may be prescribed when symptoms of a sinus infection warrant such treatment. Common antibiotics for sinus infection include Augmentin, Zithromax, Levaquin, Septra, and Amoxil.
Similarly, the article published in the National Library of Medicine in February 2021 mentioned that the prevalence rate of chronic sinusitis is around 10.9% in Europe, 13% in the United States, 6.95% in South Korea, and 8% in China, which may lead to increased demand of antibiotics. For a better treatment of acute sinusitis in adults, there is a need to rethink the current approach to treatment. The development of new therapies and drugs would require lots of time, effort, scientific research, and capital. As a result, players are stepping up their R&D efforts to provide better alternative solutions for treating patients suffering from sinusitis.
North America accounted for a significant share of the sinusitis treatment market because of the high prevalence rate of sinusitis.
As per the article titled ' Sinusitis' published in May 2022, sinusitis is one of the most common reasons for clinical visits in the United States and leads to 73 million restricted-activity days over one year. In addition, the health awareness and active presence of significant players are expected to fuel the market growth in this region. For instance, in March 2021 the United States Food and Drug Administration expanded the use of ClearUp sinus Pain relief treatment to include indications for treating congestion.
Clinical trials are another factor in market growth. For instance, in July 2022, St. Paul's Hospital, Canada launched a randomized, double-blind, placebo-controlled trial of 80 subjects to test whether a sinus power wash plus sinonasal microbiota transfer (SNMT) improves clinical outcomes in chronic sinusitis (CRS) patients within 45 days compared to a sinus power wash and sham SNMT. The investigators investigated the safety profile of SNMT to determine if SNMT-related CRS symptom improvement lasts up to 6 months. Finally, the investigators investigated how SNMT contributes to CRS recovery, by tracking changes in the sinus microbiota and inflammation pre-and post-treatment. Thus, such clinical trials are expected to provide better treatment in the region which is expected to increase the market growth.
Thus, the increasing prevalence of sinusitis, awareness campaigns, and clinical trials are expected to increase market growth over the forecast period.
The Sinusitis Treatment Market is fragmented. Major companies in the Sinusitis Treatment market are Olympus Corporation, Medtronic plc, Stryker, Cipla Ltd., Dr. Reddy's Laboratories Ltd, Intersect ENT, Inc., Sanofi SA, and Aurobindo Pharma among others.